Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Amicus Therapeutics , Inc. (NASDAQ:FOLD), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $2.75 billion, announced today the filing of a legal opinion related to its common stock in connection with a prospectus supplement dated February 21, 2025. This filing pertains to the registration of unsold shares under the company’s at-the-market program, which was established on November 7, 2022. According to InvestingPro data, the company maintains impressive gross profit margins of nearly 90% and has demonstrated strong revenue growth of 32% over the last twelve months.
The prospectus supplement registers the remaining shares of common stock that have not yet been sold under the existing at-the-market program. This program falls under the registration statement on Form S-3 filed on February 19, 2025. The opinion, provided by Troutman Pepper Locke LLP, confirms the legality of the shares being offered.
Amicus Therapeutics, headquartered in Princeton, New Jersey, is known for its focus on developing therapies for rare and orphan diseases. The company’s decision to file this prospectus supplement is part of its ongoing efforts to facilitate the sale of its common stock, which trades on the Nasdaq exchange under the ticker symbol FOLD. Currently trading near its 52-week low of $8.79, InvestingPro analysis suggests the stock is undervalued, with analysts setting price targets ranging from $12 to $21 per share. For deeper insights into Amicus’s valuation and growth prospects, check out the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
The filing of the prospectus supplement and the legal opinion does not necessarily indicate that any sales will take place immediately but ensures the company has the flexibility to sell shares in the future under the at-the-market program. The inclusion of the legal opinion is a standard procedure to comply with regulatory requirements and provide transparency to investors.
The company’s shares of common stock have been registered with the Securities and Exchange Commission (SEC), and the details of the opinion by Troutman Pepper Locke LLP have been included as Exhibit 5.1 in the Form 8-K filed today. The consent of Troutman Pepper Locke LLP is also included within the same exhibit, as required by SEC regulations.
This filing comes as part of Amicus Therapeutics’ regular financial reporting and does not necessarily reflect any immediate changes in the company’s operations or financial position. The company maintains a healthy financial position with liquid assets exceeding short-term obligations, as evidenced by a strong current ratio of 3.39. The information is based on the company’s latest SEC filing and is intended for informational purposes only. Discover more financial metrics and 12 additional exclusive ProTips for Amicus Therapeutics on InvestingPro.
In other recent news, Amicus Therapeutics reported its fiscal year 2024 revenue, showing a 33% increase to $528.3 million. The company’s key product, Galafold, contributed $458.2 million to this total, reflecting a 19% year-over-year growth. Analysts at BofA Securities revised their price target for Amicus to $14, maintaining a Buy rating, while Goldman Sachs reiterated a Neutral rating with the same price target. Amicus’s revenue projections for 2025 suggest a 10%-15% growth for Galafold, with Pombiliti+Opfolda expected to increase by 65%-85%. Despite a downgrade from Morgan Stanley (NYSE:MS) to an Equalweight rating, the firm acknowledged the company’s strong performance and achievements, including a favorable settlement with Teva over Galafold’s patent. Amicus anticipates exceeding $1 billion in total revenue by 2028, with Galafold sales projected to reach $1 billion by 2037. The company also expects to achieve positive GAAP net income in the latter half of 2024. Investors are closely watching Amicus’s strategic approach to managing expectations and its long-term revenue potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.